Depo-Provera Lawsuit Update March 2026, Trials, Pfizer’s Defense and What Victims Need to Know
More than 2,000 women have filed federal lawsuits against Pfizer alleging that its injectable birth control Depo-Provera caused them to develop brain tumors — and the litigation is growing rapidly. As of March 2026, the cases are consolidated in federal court in Florida, a critical pretrial ruling is pending, and the first trial is targeted for December 2026. This article explains the current state of the litigation, what the science shows, and what affected women should understand about the legal process.
What Is Depo-Provera?
Depo-Provera is the brand name for medroxyprogesterone acetate (MPA), an injectable form of birth control made by Pfizer. It works by blocking the release of an egg from the ovaries during the reproductive cycle. Users receive a shot — commonly called the Depo shot or birth control shot — every three months, injected into the arm or buttocks.
Depo-Provera has been available in the United States since the FDA first approved it in 1992. Millions of women have used it as a long-term contraceptive option over the past three decades.
What Is a Meningioma and What Does the Science Say?
A meningioma is a tumor that grows in the meninges — the protective membranes surrounding the brain and spinal cord. Most meningiomas are non-malignant, but they can still cause serious symptoms depending on their location and size, including severe headaches, vision problems, hearing loss, cognitive difficulties, and in some cases the need for brain surgery.
The scientific concern linking Depo-Provera to meningiomas is not new. Studies linking Depo-Provera to meningioma go back to 1983, when researchers discovered that synthetic hormones could stimulate progesterone receptors in these tumors.
The litigation accelerated dramatically after a major study in March 2024. A BMJ study found that women using the birth control shot for over a year were 5.6 times more likely to develop a meningioma. A follow-up study published in JAMA Neurology in 2025 reinforced those findings, with increased risk primarily seen in patients with more than four years of exposure.
Why Did the US Take So Long to Add a Warning?
This is a central question in the litigation. The FDA’s warning came more than 33 years after Depo-Provera’s initial FDA approval in 1992 and nearly two years after the key BMJ study was published in March 2024. Other countries, including Canada, the United Kingdom, and the European Union, had added meningioma warnings to Depo-Provera packaging before the U.S.
The FDA formally approved a label change for Depo-Provera in December 2025, adding language stating: “Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma. Discontinue Depo-Provera CI if a meningioma is diagnosed.”
Plaintiffs argue this decades-long delay — while other countries acted — is central evidence that Pfizer knew about the risk and failed to warn American consumers.
Where Does the Litigation Stand in March 2026?
As of February 2026, 2,098 cases are pending before Judge M. Casey Rodgers in the U.S. District Court for the Northern District of Florida under MDL No. 3140. But the true scale is likely far larger. Plaintiffs’ lawyers report holding onto nearly 10,000 unfiled cases, waiting to see how key pretrial rulings unfold before filing.
March 2026 — Leadership Reappointment: A federal judge called for attorneys to reapply for leadership positions in the Depo-Provera MDL before their one-year appointment expires in March 2026. Early in the federal litigation, Judge Rodgers appointed a group of 63 lawyers to Depo-Provera leadership positions, tasked with coordinating discovery and pretrial proceedings on behalf of all plaintiffs.
Monthly Case Management Conferences: The judge has issued a pretrial order setting monthly Case Management Conferences throughout 2026, all held at the U.S. District Courthouse in Pensacola, Florida. During these hearings, the judge and attorneys review timelines, resolve disputes, and plan the next phases of the litigation.
Five Bellwether Cases Selected: Five cases have been selected as test trials that will likely impact all cases in the Depo-Provera litigation. One of them involves a New Jersey woman who alleges Depo-Provera injections she received from 2000 through 2020 caused her to develop multiple meningiomas. She began experiencing severe headaches and arm twitching at age 36 and was later diagnosed with a second brain tumor at age 45.
Judge Rodgers has indicated she wants the first Depo-Provera bellwether trial ready by December 7 or 14, 2026, with remaining trials beginning in January 2027.
What Is a Bellwether Trial and Why Does It Matter?
A bellwether trial is a test case — a small number of representative lawsuits tried before a jury to gauge how juries respond to the evidence and arguments. The results are not legally binding on other plaintiffs, but they carry enormous practical weight.
If early bellwether verdicts favor plaintiffs, it puts significant pressure on Pfizer to settle the remaining thousands of cases. If verdicts favor Pfizer, settlement values may drop and some plaintiffs may withdraw claims. The December 2026 trial date is arguably the most important milestone in this entire litigation.
The Pfizer Preemption Argument — The Biggest Legal Threat to All Cases
The single most significant pending legal issue is Pfizer’s federal preemption motion. Pfizer has filed a motion for summary judgment based on federal preemption, essentially asking the judge to dismiss the key claims without holding a trial. Pfizer argues these lawsuits should not move forward since the FDA previously rejected a label update for Depo-Provera that would have included meningioma information.
In plain terms: Pfizer is arguing that because it asked the FDA to add a warning and the FDA said no at the time, it cannot be held liable for failing to warn — the federal regulatory process preempts the state law failure-to-warn claims that form the backbone of the litigation.
Judge Rodgers has noted that her ruling on this motion will apply across the entire MDL and will also take into account the FDA’s recent decision to add the warning label. If the court rejects Pfizer’s preemption argument, the litigation moves to the expert testimony phase, expected to begin in spring 2026. If the court accepts it, thousands of cases could be dismissed. This ruling is the most closely watched development in the litigation right now.
This Is an MDL — Not a Class Action
A common point of confusion is whether this is a class action lawsuit. It is not. Depo-Provera cases are part of multidistrict litigation (MDL), not a class action. Each case is handled individually.
In a class action, all plaintiffs share one outcome. In an MDL, individual cases are grouped under one judge for efficiency — coordinated discovery, shared expert witnesses, and unified pretrial proceedings — but each plaintiff’s case is ultimately decided on its own facts. This means each woman’s individual medical history, duration of use, and tumor severity will determine her specific outcome and any potential compensation.
What Damages May Be Available?
No Depo-Provera settlements have been announced as of March 2026. Average verdicts involving meningiomas from prior unrelated cases have exceeded $3 million, with settlements averaging around $868,000. These figures are not guarantees — they come from a different category of meningioma cases involving failure to diagnose, not pharmaceutical liability.
Some attorneys estimate a Depo shot settlement could range from $100,000 to $500,000 or more based on similar drug injury cases, but these figures are only estimates. Actual compensation, if any, will depend on individual medical records, duration of use, severity of the tumor, level of disability, and the strength of each claim.
Statute of Limitations — Act Carefully
Most states allow two to three years from the time you discover the link between Depo-Provera and your tumor. Some states offer additional time for fraudulent concealment claims. The December 2025 FDA label change may also reset the clock for some women — the new warning may affect the statute of limitations for some plaintiffs, as it could reset when the “discovery clock” began for women who were unaware of the connection between Depo-Provera and their brain tumor.
State deadlines vary significantly. Consulting a qualified attorney promptly is the most reliable way to determine whether your claim may still be timely.
FAQs
Is the Depo-Provera lawsuit a class action?
No. The lawsuits are being handled as an MDL, not a class action. Each case is filed individually and decided on its own facts, though all cases are coordinated before one judge in Florida for pretrial proceedings.
How many lawsuits have been filed against Pfizer over Depo-Provera?
As of March 2026, at least 2,098 Depo-Provera lawsuits have been consolidated into the MDL in the Northern District of Florida. Attorneys report holding thousands of additional unfiled cases awaiting key pretrial rulings.
What does the science say about Depo-Provera and brain tumors?
A 2024 BMJ study found that women using Depo-Provera for over a year were 5.6 times more likely to develop a meningioma. A 2025 JAMA Neurology study reinforced those findings, with elevated risk seen primarily in patients with more than four years of use.
When did the FDA add a meningioma warning to Depo-Provera?
As of December 2025, the Depo-Provera label was updated to warn of an increased risk of meningioma. The U.S. was behind Canada, the UK, and the EU, all of which had already added similar warnings.
What is the biggest legal obstacle facing plaintiffs right now?
Pfizer’s federal preemption motion — arguing the FDA’s prior rejection of a warning label shields it from liability — is the most critical pending issue. Judge Rodgers’ ruling on this motion will affect all 2,098 cases in the MDL.
When is the first Depo-Provera trial expected?
Judge Rodgers has indicated she wants the first bellwether trial ready by December 7 or 14, 2026, with remaining trials beginning in January 2027.
Who may qualify to file a claim?
To qualify, you generally must have used Depo-Provera or Depo-SubQ Provera for at least one year and been diagnosed with an intracranial meningioma. Eligibility also depends on your state’s statute of limitations. Consulting a qualified attorney is the best way to assess your specific situation.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. Laws and legal procedures vary by jurisdiction and may change over time. For advice regarding a specific situation, consult a qualified attorney or the appropriate authority.
About the Author
Sarah Klein, JD, is a licensed attorney and legal content strategist with over 12 years of experience across civil, criminal, family, and regulatory law. At All About Lawyer, she covers a wide range of legal topics — from high-profile lawsuits and courtroom stories to state traffic laws and everyday legal questions — all with a focus on accuracy, clarity, and public understanding.
Her writing blends real legal insight with plain-English explanations, helping readers stay informed and legally aware.
Read more about Sarah